Predict your next investment

Venture Capital
agentcapital.com

See what CB Insights has to offer

Investments

23

Portfolio Exits

7

Funds

2

About Agent Capital

Agent Capital is a health care venture capital firm focused on investing in therapeutics and technology platforms that address the unmet patient need.

Agent Capital Headquarter Location

1400 Main Street, Floor 1

Waltham, Massachusetts, 02451,

United States

(617) 340-2538

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Agent Capital News

Affini-T Therapeutics Closes $175M Financing

Mar 23, 2022

Affini-T Therapeutics Closes $175M Financing Affini-T Therapeutics , a Boston, MA, and Seattle, WA-based biotechnology company, raised $175M in funding. The round was led by Vida Ventures and Leaps by Bayer, with participation from Humboldt Fund, The Parker Institute for Cancer Immunotherapy, Catalio Capital Management, Agent Capital, Alexandria Venture Investments, Erasca Ventures, and Fred Hutchinson Cancer Research Center. The company intends to use the funds to operationalize its platform discovery engine and seek to drive multiple oncogene driver programs into the clinic while pursuing complementary technology licenses to bolster its cell therapy platform. Led by Jak Knowles, M.D., Co-Founder, President and Chief Executive Officer, Affini-T leverages T cells to target core oncogenic drivers to develop potentially curative therapies for solid tumor cancers. Its cell therapy platform harnesses engineering and synthetic biology capabilities to target cancer-driving mutations, beginning with KRAS. The company leverages these tools to optimize T cell functions and rewrite the rules of the solid tumor microenvironment, enabling the potential for sustained clinical outcomes in patients. The company has established a bi-coastal U.S. presence with research labs in Seattle, Washington and headquarters and manufacturing infrastructure in Boston, Massachusetts. Affini-T is led by Dr. Knowles, Loïc Vincent, Ph.D., Chief Scientific Officer, Kim Nguyen, Ph.D., Chief Technical Officer and Kathy Yi, MBA, Chief Operating Officer. The company was also co-founded by Arjun Goyal, M.D., M.Phil., Co-Founder and Managing Director, Vida Ventures. Affini-T has also established a scientific advisory board comprised of its scientific co-founders from Fred Hutch and key innovators in immunology, tumor microenvironment biology and cellular engineering including: Jim Allison, Ph.D., Nobel Laureate, MD Anderson Cancer Center; Pam Sharma, M.D., Ph.D., MD Anderson Cancer Center; Rafi Ahmed, Ph.D., Emory University; David Kranz, Ph.D., University of Illinois; and Susan Kaech, Ph.D., Salk Institute. FinSMEs 23/03/2022

Agent Capital Investments

23 Investments

Agent Capital has made 23 investments. Their latest investment was in Affini-T Therapeutics as part of their Series A on March 3, 2022.

CBI Logo

Agent Capital Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

3/22/2022

Series A

Affini-T Therapeutics

$175M

Yes

17

1/25/2022

Series A

Carbon Biosciences

$38M

Yes

1

8/18/2021

Series B

Immunitas Therapeutics

$58M

Yes

15

7/6/2021

Series B

Subscribe to see more

$99M

Subscribe to see more

10

5/18/2021

Series A

Subscribe to see more

$99M

Subscribe to see more

10

Date

3/22/2022

1/25/2022

8/18/2021

7/6/2021

5/18/2021

Round

Series A

Series A

Series B

Series B

Series A

Company

Affini-T Therapeutics

Carbon Biosciences

Immunitas Therapeutics

Subscribe to see more

Subscribe to see more

Amount

$175M

$38M

$58M

$99M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

17

1

15

10

10

Agent Capital Portfolio Exits

7 Portfolio Exits

Agent Capital has 7 portfolio exits. Their latest portfolio exit was Entrada Therapeutics on October 29, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

10/29/2021

IPO

$99M

7

10/8/2021

IPO

Subscribe to see more

Subscribe to see more

10

9/15/2021

IPO

Subscribe to see more

$99M

Subscribe to see more

10

6/3/2020

IPO

Subscribe to see more

$99M

Subscribe to see more

10

3/28/2019

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

10/29/2021

10/8/2021

9/15/2021

6/3/2020

3/28/2019

Exit

IPO

IPO

IPO

IPO

IPO

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

7

10

10

10

10

Agent Capital Fund History

2 Fund Histories

Agent Capital has 2 funds, including Agent Capital Fund II.

Closing Date

Fund

Fund Type

Status

Amount

Sources

5/21/2021

Agent Capital Fund II

$53M

1

11/20/2019

Agent Capital Fund I

Subscribe to see more

Subscribe to see more

$99M

10

Closing Date

5/21/2021

11/20/2019

Fund

Agent Capital Fund II

Agent Capital Fund I

Fund Type

Subscribe to see more

Status

Subscribe to see more

Amount

$53M

$99M

Sources

1

10

Agent Capital Team

1 Team Member

Agent Capital has 1 team member, including current Founder, Managing Partner, Geeta Vemuri.

Name

Work History

Title

Status

Geeta Vemuri

Founder, Managing Partner

Current

Name

Geeta Vemuri

Work History

Title

Founder, Managing Partner

Status

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.